TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26699168

Group type: EXPERIMENTAL
Intervention: Selexipag (maximum dose, 1600 μg twice daily)
Number of subjects: 1156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1156

Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 1156
Study: 20814970

Group type: EXPERIMENTAL
Intervention: Intravenous neridronate (100 mg infusion for 2 consecutive days)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Intramuscular neridronate (25 mg injection weekly for 2 months)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 56
Study: 18053632

Group type: EXPERIMENTAL
Intervention: 50 mg naltrexone
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 16469206

Group type: EXPERIMENTAL
Intervention: Propofol-based general anaesthesia
Number of subjects: 70

Group type: COMPARATOR
Intervention: Thiopental-sevoflurane-based anaesthesia
Number of subjects: 70
Study: 12830671

Group type: EXPERIMENTAL
Intervention: Non-informed group (unaware of the storing capacity of the device)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Informed group (aware of the storing capacity of the device)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Non-informed group
Number of subjects: 48
Study: 11023759

Group type: EXPERIMENTAL
Intervention: Imiquimod 2% cream
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 8828528

Group type: EXPERIMENTAL
Intervention: Optimal treatment of asthma based on the International Consensus Report on the Management of Asthma
Number of subjects: 0
Study: 1405323

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (15, 50, or 150 U/kg) given intravenously every other day for four injections
Number of subjects: 46
Study: 3902377

Group type: EXPERIMENTAL
Intervention: New suppositories (800 mg paracetamol, 16 mg codeine phosphate, 12.5 mg buclizine hydrochloride)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Old suppositories (800 mg paracetamol, 16 mg codeine phosphate, 12.5 mg buclizine hydrochloride)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: New suppositories
Number of subjects: 10

Group type: COMPARATOR
Intervention: Old suppositories
Number of subjects: 10
Study: 31329819

Group type: EXPERIMENTAL
Intervention: Cognitive Distraction
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Physical Distraction
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard Administration
Number of subjects: 33
Study: 27766347

Group type: EXPERIMENTAL
Intervention: Intensive glycaemia intervention
Number of subjects: 1328

Group type: COMPARATOR
Intervention: Standard management of hyperglycaemia
Number of subjects: 1328

Group type: COMPARATOR
Intervention: BP intervention
Number of subjects: 1328

Group type: COMPARATOR
Intervention: Lipid intervention
Number of subjects: 1328
Study: 27919285

Group type: EXPERIMENTAL
Intervention: Active treatment (EN-PENS)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control treatment (sham)
Number of subjects: 76
Study: 23740399

Group type: EXPERIMENTAL
Intervention: Local infiltration with sodium bicarbonate as an adjunct to 2% lignocaine and 1:80,000 adrenaline
Number of subjects: 200

Group type: COMPARATOR
Intervention: Local infiltration with 2% lignocaine and 1:80,000 adrenaline
Number of subjects: 200
Study: 22392172

Group type: EXPERIMENTAL
Intervention: Clinic-integrated behavioral intervention
Number of subjects: 390
Study: 19027313

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 199

Group type: COMPARATOR
Intervention: Tranexamic acid
Number of subjects: 199
Study: 17418038

Group type: EXPERIMENTAL
Intervention: Progesterone (PG) treatment group
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study: 15229622

Group type: EXPERIMENTAL
Intervention: Statin + ACEI (Group A)
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Statin only (Group B)
Number of subjects: 1600

Group type: COMPARATOR
Intervention: ACEI only (Group C)
Number of subjects: 1600

Group type: COMPARATOR
Intervention: No treatment (Group D)
Number of subjects: 1600
Study: 11980769

Group type: EXPERIMENTAL
Intervention: Trimegestone 0.25 mg/day combined with continuous E(2) 2 mg/day
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Trimegestone 0.5 mg/day
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Trimegestone 0.05 mg and 0.1 mg
Number of subjects: 134
Study: 10431997

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (0.27 mmol/kg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 7587856

Group type: EXPERIMENTAL
Intervention: Preprandial regular insulin combined with glibenclamide (group D)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bedtime NPH insulin combined with glibenclamide (group N)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 80
Study: 2119355

Group type: EXPERIMENTAL
Intervention: Ritanserin
Number of subjects: 38

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ritanserin and Amitriptyline
Number of subjects: 38
Study: 6153603

Group type: EXPERIMENTAL
Intervention: alpha‐contingent stimulation
Number of subjects: 24

Group type: COMPARATOR
Intervention: random (non‐contingent) stimulation
Number of subjects: 24
Study: 6499724

Group type: EXPERIMENTAL
Intervention: Smoking one cigarette
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no smoking)
Number of subjects: 18
Study: 29949174

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine hydrochloride combined with etomidate fat emulsion (Group C)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine hydrochloride (Group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Etomidate fat emulsion (Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (Group A and B)
Number of subjects: 90
Study: 27609856

Group type: EXPERIMENTAL
Intervention: In-centre nocturnal haemodialysis (INHD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional daytime dialysis
Number of subjects: 0
Study: 24714349

Group type: EXPERIMENTAL
Intervention: Minimally invasive (MI) approach
Number of subjects: 160

Group type: COMPARATOR
Intervention: Median sternotomy (MS) approach
Number of subjects: 160
Study: 22976655

Group type: EXPERIMENTAL
Intervention: 2-phase treatment (Twin Block therapy followed by fixed appliance therapy with nonextraction)
Number of subjects: 146

Group type: COMPARATOR
Intervention: 1-phase treatment (fixed appliance therapy with extraction of 4 first premolars)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: 2-phase treatment
Number of subjects: 146

Group type: COMPARATOR
Intervention: 1-phase treatment
Number of subjects: 146
Study: 20210799

Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation (PBI)
Number of subjects: 1140

Group type: COMPARATOR
Intervention: Whole Breast Radiation Therapy (WBRT)
Number of subjects: 1140
Study: 18321879

Group type: EXPERIMENTAL
Intervention: Kalon herpes simplex virus type 2 ELISA (index value of 1.5)
Number of subjects: 820
Study: 15202583

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective estrogen receptor modifiers
Number of subjects: 0
Study: 12041926

Group type: EXPERIMENTAL
Intervention: Group A (7 patients with acute gastrointestinal perforation)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Group B (5 critically ill patients)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (10 controls)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Group A and B
Number of subjects: 22
Study: 9394687

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (providing approximately 1672 kJ (400 kcal) energy/d)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (for those who received it before age 18 months, n = 73)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 231
Study: 7944506

Group type: EXPERIMENTAL
Intervention: 400 IU of oral vitamin E (alpha-tocopherol acetate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3225767

Group type: EXPERIMENTAL
Intervention: 5-mg immediate release (IR) tablet given twice daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: 5-mg sustained-release (SR) capsule formulations given daily
Number of subjects: 24
Study: 29673631

Group type: EXPERIMENTAL
Intervention: iHPC (prechopping method using a Reverse Chopper)
Number of subjects: 32
Study: 26621854

Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 24981319

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 200 mg subcutaneously every 2 weeks (induction dosing: 400 mg at Weeks 0, 2, and 4)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) with non-MTX DMARDs
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) monotherapy
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 230
Study: 23049823

Group type: EXPERIMENTAL
Intervention: RC‐5000 (Tomey Corp., Japan)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: KR‐8000 (Topcon, Japan)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: IOLMaster (Carl Zeiss Meditec, Germany)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: E300 (Medmont International, Australia)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Allegro Topolyzer (Wavelight AG, Germany)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Vista (EyeSys, TX)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Pentacam (Oculus, Germany)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Sirius (CSO, Italy)
Number of subjects: 35

Group type: COMPARATOR
Intervention: EyeSys Vista and Medmont E300
Number of subjects: 35
Study: 20974604

Group type: EXPERIMENTAL
Intervention: GW274150 60 mg
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: GW274150 120 mg
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: GW274150 60 mg (Part 2)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Placebo (Part 1)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Placebo (Part 2)
Number of subjects: 366
Study: 17697915

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 9193
Study: 16141420

Group type: EXPERIMENTAL
Intervention: Active treatment (2 to 4 mg perindopril plus 2.0 to 2.5 mg indapamide for those without contraindications)
Number of subjects: 476
Study: 11952446

Group type: EXPERIMENTAL
Intervention: Intra-articular 20 mL 0.5% bupivacaine with epinephrine (B + E‐group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline with epinephrine (S + E‐group)
Number of subjects: 120
Study: 9772936

Group type: EXPERIMENTAL
Intervention: Indapamide 1.5 mg sustained release
Number of subjects: 690
Study: 7531877

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2535914

Group type: EXPERIMENTAL
Intervention: Saccomanno technique
Number of subjects: 103

Group type: COMPARATOR
Intervention: Fresh smears
Number of subjects: 103
Study: 162676

Group type: EXPERIMENTAL
Intervention: Mazindol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diethylpropion
Number of subjects: 50
Study: 31788825

Group type: EXPERIMENTAL
Intervention: Psychoeducation based on a cognitive-behavioral approach (5 sessions over 4 weeks)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Psychoeducation based on a cognitive-behavioral approach
Number of subjects: 90
Study: 31783672

Group type: EXPERIMENTAL
Intervention: Individualized nutritional intervention program (iNIP)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 82
Study: 28658026

Group type: EXPERIMENTAL
Intervention: 150 mL/min
Number of subjects: 100

Group type: COMPARATOR
Intervention: 250 mL/min
Number of subjects: 100
Study: 27063854

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg plus Solifenacin 5 mg
Number of subjects: 2174

Group type: COMPARATOR
Intervention: Solifenacin 5 mg
Number of subjects: 2174

Group type: COMPARATOR
Intervention: Solifenacin 10 mg
Number of subjects: 2174
Study: 25189764

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT) with blood glucose target between 4.4 and 6 mmol.L(‐1)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Conventional glucose management with blood glucose target between 5.5 and 9 mmol.L(‐1)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Conventional glucose management
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 188
Study: 22930999

Group type: EXPERIMENTAL
Intervention: Trait expectancies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stereotype expectancies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 19288080

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) in femoral tunnels at the end of surgery (Group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) in femoral tunnels at the end of surgery and intra-articular at 2- and 4 weeks after surgery (Group C)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) activated with thrombin in the femoral tunnels (Group D)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No platelet-rich plasma (Group A)
Number of subjects: 40
Study: 17594856

Group type: EXPERIMENTAL
Intervention: Canned tuna in olive oil with isoflavones
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Canned tuna in olive oil with omega-3 fatty acids
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Canned tuna in olive oil with phytosterols
Number of subjects: 400

Group type: COMPARATOR
Intervention: Canned tuna in olive oil alone (control group)
Number of subjects: 400
Study: 15099664

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (32/8 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (16/4 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (8/2 mg)
Number of subjects: 8
Study: 12238830

Group type: EXPERIMENTAL
Intervention: Sotalol (80 mg twice daily for 5 days starting from the morning of the first postoperative day)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Magnesium (1.5 g daily for 6 days starting in the operating room just before cardiopulmonary bypass)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Sotalol and Magnesium (both at the same dosages)
Number of subjects: 207

Group type: COMPARATOR
Intervention: No antiarrhythmic agents (Control group)
Number of subjects: 207
Study: 10548619

Group type: EXPERIMENTAL
Intervention: Laparoscopic salpingectomy
Number of subjects: 204

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 204
Study: 7696074

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.75 mg kg‐1 administered 5 or 10 min after mivacurium, or when T1 had recovered to 5, 10, 25 or 50% of control.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Spontaneous recovery (control group).
Number of subjects: 70
Study: 1708197

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 341
Study: 727903

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Combined phenelzine and amitriptyline
Number of subjects: 17
Study: 31295904

Group type: EXPERIMENTAL
Intervention: Juggling while practicing multiplication tables (intervention group)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Sedentary practice of multiplication tables (control group)
Number of subjects: 312
Study: 28635196

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 3900

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 3900
Study: 25862297

Group type: EXPERIMENTAL
Intervention: 4-week multispecies probiotics intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: inert placebo
Number of subjects: 20
Study: 23939325

Group type: EXPERIMENTAL
Intervention: Beating heart (group A)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Arrested heart (group B)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 21216483

Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stem cells (BMMSCs)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Bone marrow-derived mononuclear cells (BMMNCs)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 41
Study: 19104202

Group type: EXPERIMENTAL
Intervention: First-line chemotherapy for metastatic breast cancer
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Coping strategies (work, social support, church attendance)
Number of subjects: 20
Study: 17760284

Group type: EXPERIMENTAL
Intervention: Finger probe (Ox‐1)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Ear probe (Ox‐1)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Finger probe (Ox‐2)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Ear probe (Ox‐2)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Finger probes (both Ox‐1 and Ox‐2)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Ear probes
Number of subjects: 7
Study: 15105197

Group type: EXPERIMENTAL
Intervention: Interactive music therapy
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Oral midazolam
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control
Number of subjects: 123
Study: 11446541

Group type: EXPERIMENTAL
Intervention: Hard spine board
Number of subjects: 18

Group type: COMPARATOR
Intervention: Red vacuum mattress splint
Number of subjects: 18

Group type: COMPARATOR
Intervention: Blue vacuum mattress splint
Number of subjects: 18
Study: 9498031

Group type: EXPERIMENTAL
Intervention: Trial detergent with added enzymes
Number of subjects: 25

Group type: COMPARATOR
Intervention: Trial detergent without added enzymes
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Normal washing detergent
Number of subjects: 25
Study: 1454497

Group type: EXPERIMENTAL
Intervention: Mirror training in three dimensions (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No training (Group B, Control)
Number of subjects: 60
Study: 2869714

Group type: EXPERIMENTAL
Intervention: apalcillin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: piperacillin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: mezlocillin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: azlocillin
Number of subjects: 6
Study: 30322737

Group type: EXPERIMENTAL
Intervention: Leap motion control (LMC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (traditional OT for 60min)
Number of subjects: 16
Study: 29511807

Group type: COMPARATOR
Intervention: D-amphetamine (40 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: lisdexamfetamine (100 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 26370220

Group type: EXPERIMENTAL
Intervention: Sotatercept 0.3 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sotatercept 0.5 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sotatercept 0.1 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24608361

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4) 60 mg/kg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 23130754

Group type: EXPERIMENTAL
Intervention: Opportunistic case finding for Atrial Fibrillation by Experimental Group practitioners
Number of subjects: 12870

Group type: COMPARATOR
Intervention: Regular guidelines followed by Control Group practitioners
Number of subjects: 12870
Study: 20073227

Group type: EXPERIMENTAL
Intervention: Anti-anaphylaxis Granule (AAG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cetirizine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 0
Study: 17322014

Group type: EXPERIMENTAL
Intervention: Listening to music for 60 minutes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Resting quietly for 60 minutes (Control)
Number of subjects: 10
Study: 15213033

Group type: EXPERIMENTAL
Intervention: L-Rhamnose
Number of subjects: 22

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 22

Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 22
Study: 11153185

Group type: EXPERIMENTAL
Intervention: Cooling via convection (airflow blanket)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Cooling via conduction (water-flow blanket)
Number of subjects: 37
Study: 9681082

Group type: EXPERIMENTAL
Intervention: Dexamethasone plus granisetron (1 mg b.d. p.o.)
Number of subjects: 654

Group type: COMPARATOR
Intervention: Dexamethasone (8 mg b.d. p.o.)
Number of subjects: 654
Study: 7612714

Group type: EXPERIMENTAL
Intervention: Subclavian vein access (Group A)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Peripheral access via veins of the flexion side of the elbow (Group B)
Number of subjects: 87
Study: 2774123

Group type: EXPERIMENTAL
Intervention: Open-end (single hole) epidural catheters
Number of subjects: 802

Group type: COMPARATOR
Intervention: Closed-end (three lateral holes) epidural catheters
Number of subjects: 802
Study: 356968

Group type: EXPERIMENTAL
Intervention: Intensive C. parvum immunotherapy
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Nonintensive C. parvum immunotherapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no C. parvum)
Number of subjects: 49
Study: 31268989

Group type: EXPERIMENTAL
Intervention: WPPE (with personal protective equipment, load = 8.3 kg)
Number of subjects: 19
Study: 31101080

Group type: EXPERIMENTAL
Intervention: 30-degree PLR position
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 50-degree PLR position
Number of subjects: 82

Group type: COMPARATOR
Intervention: 0-degree PLR position (supine)
Number of subjects: 82

Group type: COMPARATOR
Intervention: 0-degree PLR position
Number of subjects: 82
Study: 28119232

Group type: EXPERIMENTAL
Intervention: 12-month progressive home exercise program (EG)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual care (CG)
Number of subjects: 108